The UK’s Technology Strategy Board has awarded Domainex a £250,000 grant to develop of a new drug to treat several common cancers.
The drug will act by inhibiting two protein kinases, TBK1 and IKKe, which will suppress certain cancer cell lines from growing.
Go deeper with GlobalData
The aim of the project is to identify a drug candidate that is effective in disease models and would be orally well-absorbed by humans.
Domainex research director Trevor Perrior said that the novel mode of action will allow the treatment of patients with drug-resistant, triple-negative tumours.
The marketing of the new drug will be done in partnership with a large pharmaceutical company that has the ability to conduct drug trials, Domainex said.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
